Podcasts about Selumetinib

  • 18PODCASTS
  • 27EPISODES
  • 9mAVG DURATION
  • ?INFREQUENT EPISODES
  • Jul 1, 2022LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about Selumetinib

Latest podcast episodes about Selumetinib

Neuro-Oncology: The Podcast
Selumetinib in children with NF1 and plexiform neurofibroma

Neuro-Oncology: The Podcast

Play Episode Listen Later Jul 1, 2022 23:36


Dr.Iyad Alnahhas interviews Drs. Andrea Gross and Brigitte Widemann about their manuscript entitled "Selumetinib in Children with Neurofibromatosis Type 1 and Asymptomatic Inoperable Plexiform Neurofibroma at Risk for Developing Tumor-Related Morbidity", published online in Neuro-Oncology in April 2022. Full Article

CCO Oncology Podcast
Expert Answers to Questions on Managing Neurofibromatosis Type 1 and MEK Inhibitors for NF1-Associated Plexiform Neurofibromas

CCO Oncology Podcast

Play Episode Listen Later Jul 12, 2021 13:36


In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:  Whole exome sequencing for diagnosisWhen to treat asymptomatic tumorsGenetic testing of family membersChoosing a MEK inhibitorSupportive care for acneiform rashOther RAS pathway inhibitorsPresenters:Scott R. Plotkin, MD, PhDExecutive DirectorPappas Center for Neuro-OncologyProfessor of NeurologyHarvard Medical SchoolBoston, MassachusettsBrian D. Weiss, MDClinical Professor of PediatricsCancer and Blood Diseases Institute Division of Oncology  Medical DirectorSolid Tumor ProgramCincinnati Children's Hospital Medical CenterCincinnati, OhioLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3AXckHQ

Se escucha fuerte
Resumen de noticias SC online 01-05-21

Se escucha fuerte

Play Episode Listen Later May 1, 2021 4:28


A continuación un breve resumen de las principales noticias del diario electrónico San Carlos On line para este día sábado 1 de mayo de 2021 Casos de COVID-19 descendieron por “la baja en los testeos informados” Afirma el Secretario del Colmed NACIONAL.- (El Desconcierto).- Pese a que en el Minsal han celebrado la baja en los casos nuevos de coronavirus, luego que hace pocas semanas se llegara al escenario de los 9.000 contagiados diarios, desde el Colegio Médico afirman que el declive se generó solo porque se realizaron menos exámenes de PCR. “Hoy los números están peor que cuando se suspendieron las elecciones”, sostuvieron. José Miguel Bernucci, secretario general del Colegio Médico de Chile, advirtió que la baja en los casos nuevos de coronavirus que ha ido informando el Ministerio de Salud durante los reportes diarios, no se debe a que la pandemia esté cediendo. En San Carlos está el 22% de los casos activos de la región de Ñuble LOCAL..- El alto número de contagiados y las cifras en general no han variado en San Carlos, comuna que lleva más de un mes en cuarentena, fase1, en un panorama que se espera cambie a partir de los resultados que se obtengan de las medidas adoptadas, principalmente, por la autoridad militar de aumentar en un 30% el contingente en esta comuna. Es en esta comuna donde reside el 22% de los casos activos de la región, y que en lo que va del año ha cuadriplicado sus contagios respecto al total del 2020, acumulando solo en el mes de abril 891 confirmaciones de COVID-19 y una positividad del 21%. Jefe de zona se refiere al aumento de fiscalización en San Carlos LOCAL.- La autoridad militar en la zona, coronel jefe de zona, Jeffrey Bagatello, se refirió a la situación de San Carlos y la eventual tardanza en la decisión de aumentar la fiscalización para frenar el aumento de casos de Covid-19, señalando que el trabajo de fiscalización ha sido constante en la totalidad de las comunas bajo su jurisdicción. El jefe de la Defensa Nacional para Ñuble, Coronel Jeffrey Bagatello recordó que entre el 9 y 14 de abril hubo un aumento crítico donde se llegó a tener un 86% de la región cuarentena, dijo. Familia de Chillán realiza rifa para costear millonario tratamiento de su hija REGIONAL.- Maite es una niña de 4 años de edad residente en Chillán, diagnosticada con un neurofibroma plexiforme ciático, un tumor no operable de gran tamaño, alojado en el muslo lo que está ocasionando una atrofia muscular progresiva. Además de hospitalización y resonancia magnética cada tres meses, el tratamiento médico -de tipo oncológico- incluye un fármaco llamado SELUMETINIB, que requiere ser importado desde Estados Unidos. Cada caja tiene un costo de $6.600.000. Para su recuperación, Maite requiere dos cajas mensuales por el período de un año. Llega a su término este breve resumen de las principales noticias del diario electrónico San Carlos On line para este día sábado 1 de mayo de 2021

Understanding Childhood Cancer With Dr Geoff
The MEK inhibitors: trametinib and selumetinib

Understanding Childhood Cancer With Dr Geoff

Play Episode Listen Later Feb 19, 2021 41:14


The MEK inhibitors are a newer class of drug, and include trametinib, selumetinib and others. They have an important role in paediatric oncology, particularly in glioma treatment and in neurofibromatosis.

inhibitors mek selumetinib trametinib
Journal Club 前沿医学报导
Journal Club 儿科星期五 Episode 30

Journal Club 前沿医学报导

Play Episode Listen Later Dec 10, 2020 23:24


FDA 批准MAPK激酶抑制剂治疗手术无法切除的1型神经纤维瘤BMJ 哮喘发作与空气污染和母亲孕期吸烟有关Nature Metabolism 母亲运动带来的后代的健康获益是通过母乳中的3′-唾液酸乳糖介导的司美替尼(selumetinib)神经纤维瘤是常染色体显性遗传病,分1、2和3型。1型神经纤维瘤最常见,标志性特征是多发的牛奶咖啡斑和相关皮肤神经纤维瘤。没有针对性的总体的治疗,只能对症治疗。50%的1型神经纤维瘤患者合并丛状神经纤维瘤,丛状神经纤维瘤是一种组织学上良性的周围神经鞘肿瘤,常累及多个神经束,造成毁容、运动功能障碍、疼痛、甚至脊髓受压。司美替尼是一种MAPK激酶的抑制剂,在2020年4月,FDA批准了司美替尼用于治疗1型神经纤维瘤。《司美替尼治疗不能手术的丛状神经纤维瘤患儿》New England Journal of Medicine,2020年4月 (1)这项开放标签的2期试验,旨在确定丛状神经纤维瘤患儿服用司美替尼后的临床益处和安全性。50名、平均年龄10.2岁的、不能手术的丛状神经纤维瘤的1型神经纤维瘤病患儿入组,随机接受了司美替尼和安慰剂治疗。最常见的神经纤维瘤相关症状包括毁容(44人)、运动功能障碍(33人)和疼痛(26人)。治疗后70%达到了部分缓解,56%≥1年的持久缓解。1年后,肿瘤疼痛评分平均降低了2分,疼痛对日常功能、总体健康相关生活质量、力量和关节活动范围等多项功能结局也观察到了有临床意义的改善。其中5人因副作用停药;6人疾病发展。最常见的毒性作用为恶心、呕吐或腹泻、无症状的肌酸磷酸激酶水平升高、痤疮样皮疹及甲沟炎。结论:对于手术无法切除的丛状神经纤维瘤患儿,司美替尼产生了持久的缩小肿瘤作用。儿童哮喘哮喘(asthma)是一种异质性疾病,特点是慢性气道炎症。12岁以下儿童哮喘是最常见的儿童期慢性疾病,约80%的患儿在5岁以前出现症状,咳嗽、哮鸣、呼吸急促、胸闷胸痛是常见的症状。最常见的诱发因素包括病毒性上呼吸道感染(合胞病毒、流感病毒、鼻病毒)、运动、天气、二手烟和变应原(如尘螨、宠物毛发、花粉、霉菌)。《病例队列研究:空气污染和家庭相关因素与儿童哮喘发作和持续性喘息的关系》BMJ,2020年8月(2)研究目的探讨儿童哮喘和持续性喘息发病的危险因素(空气污染和家庭相关因素)。这项全国病例对照研究中随访了1-15岁儿童儿童哮喘发病率升高,与父母患有哮喘(风险比 2.29)、母亲在怀孕期间吸烟(风险比 1.20)相关。儿童哮喘发病率低,与父母受教育程度高(风险比0.72)和父母收入高(风险比 0.85)相关。空气污染物PM2.5和PM10与哮喘的风险增加和持续喘息相关。结论:暴露于空气污染中的儿童更容易患哮喘和持续性喘息,哮喘与父母哮喘病史、父母教育程度和母亲在怀孕期间吸烟有关。《观察性研究:母亲在怀孕期间吸烟影响子女成年后哮喘发作》European Respiratory Journal 2020年7月 (3)研究的目的是确定产前哮喘和成人哮喘发病之间的关系。研究纳入5200名、1966年芬兰北部出生的、31岁前未诊断为哮喘的人群。研究发现孕妇妊娠最后3个月吸烟,其后代31岁至46岁之间哮喘累积发病率(男性为5.1%,女性为8.8%),尤其是与无哮喘病史(风险比9.63)或咳嗽喘息病史(风险比3.21)的后代中有显著相关性。同时在妊娠期吸烟与31岁时子代的用力呼气量(FEV1)/用力肺活量(FVC)比率之间有发现了显著的相关性,在在RUNX1单倍型rs11702779-AA的后代中成年期患哮喘的风险比为5.53。结论:怀孕期间吸烟与后代成年后哮喘累积发病率有关。《观察性研究:空气污染和从出生到成年的哮喘发展》European Respiratory Journal 2020年7月 (4)空气污染对青春期至成年期哮喘发展的影响尚不清楚,研究纳入了3687个参与者,评估空气污染和哮喘发生的年龄的相关关系。研究20岁之前哮喘的发病率,与出生地空气污染物的比例增加相关(接触PM10的风险比为1.09,接触NO2的风险比为1.20)。对近期家庭居住地的空气污染进行分析后,得到了类似的结果。结论:早年暴露在空气污染中,特别是来自机动交通的污染,与儿童、青春期到成年早期罹患哮喘的风险增加有关。《哮喘患儿卧室颗粒物过滤与气道病理生理变化的关系》JAMA Pediatrics,2020年8月 (5)细颗粒物PM2.5是一种普遍存在的空气污染物,可沉积在小气道中,对哮喘起着至关重要的作用。来自杜克大学与北京上海的研究人员合作,研究PM2.5过滤装置的使用是否能改善哮喘患儿的小气道生理学和呼吸系统炎症。研究人员在患儿的卧室里随机安装了真实的过滤设备和假的过滤设备,试验前有2周的洗脱期,研究是在臭氧含量低的季节在中国上海的郊区进行的。研究纳入轻中度哮喘的、共43个、5-13岁的儿童参加了研究。室外PM2.5浓度中度升高(28.6-69.8μg/m3);经过滤的卧室PM2.5浓度比不经过滤降低63.4%。过滤的卧室空气能显著改善气道力学,总气道阻力下降24.4%,减少小气道阻力43.5%,呼气流量峰值也显著改善。这些改善与卧室PM2.5的减少显著相关。总体的小气道功能改善均没有统计学意义,但在不伴有嗜酸性气道炎症的参与者中改善显著(13.2%)。结论:室内PM2.5过滤可以通过改善气道力学和功能,减少炎症,改善哮喘患者肺部的气体流动。《VDKA研究:补充维生素D3对低维生素D和哮喘患儿哮喘加重的影响》JAMA,2020年8月 (6)研究的目的探讨维生素D3的补充是否能改善儿童哮喘和低维生素D水平严重恶化的时间。这项随机、双盲、安慰剂对照临床试验,纳入6-16岁的、哮喘严重发作高危儿童共192人,平均年龄9.8岁,女孩40%维生素D3组的37.5%和安慰剂组的34.4%出现≥1次严重恶化。补充维生素D3并没有显著改善哮喘严重恶化的时间,没有显著改善病毒诱导哮喘严重加重的时间,没有显著改善糖皮质激素剂量减量的患者比例,也没有显著减少糖皮质激素的累积剂量。两组严重不良事件相似。结论:该研究不支持在持续性哮喘和低维生素D水平的儿童维生素D3来预防哮喘加重。《前瞻性队列研究:抗生素的使用减少,影响肠道菌群和儿童哮喘发病率》Lancet Respiratory Medicine,2020年7月 (7)在欧洲和北美的一些地区,儿童哮喘的发病率正在下降;有研究提示婴儿期使用抗生素与哮喘风险增加有关。该研究的目的是验证哮喘发病率的降低是否与抗生素处方减少有关,并验证这种变化是由肠道菌群变化介导的。本研究包括基于人群和前瞻性队列分析,使用加拿大不列颠哥伦比亚省(人口400万·700万)每年抗生素处方率和哮喘诊断率的管理数据进行人群分析。2000 - 2014年,1-4岁儿童的哮喘发病率从27·3‰ 下降到20·2‰,降幅26·0%。发病率的降低与

Journal Club 前沿医学报导
Journal Club 儿科星期五 Episode 30

Journal Club 前沿医学报导

Play Episode Listen Later Dec 10, 2020 23:24


FDA 批准MAPK激酶抑制剂治疗手术无法切除的1型神经纤维瘤BMJ 哮喘发作与空气污染和母亲孕期吸烟有关Nature Metabolism 母亲运动带来的后代的健康获益是通过母乳中的3′-唾液酸乳糖介导的司美替尼(selumetinib)神经纤维瘤是常染色体显性遗传病,分1、2和3型。1型神经纤维瘤最常见,标志性特征是多发的牛奶咖啡斑和相关皮肤神经纤维瘤。没有针对性的总体的治疗,只能对症治疗。50%的1型神经纤维瘤患者合并丛状神经纤维瘤,丛状神经纤维瘤是一种组织学上良性的周围神经鞘肿瘤,常累及多个神经束,造成毁容、运动功能障碍、疼痛、甚至脊髓受压。司美替尼是一种MAPK激酶的抑制剂,在2020年4月,FDA批准了司美替尼用于治疗1型神经纤维瘤。《司美替尼治疗不能手术的丛状神经纤维瘤患儿》New England Journal of Medicine,2020年4月 (1)这项开放标签的2期试验,旨在确定丛状神经纤维瘤患儿服用司美替尼后的临床益处和安全性。50名、平均年龄10.2岁的、不能手术的丛状神经纤维瘤的1型神经纤维瘤病患儿入组,随机接受了司美替尼和安慰剂治疗。最常见的神经纤维瘤相关症状包括毁容(44人)、运动功能障碍(33人)和疼痛(26人)。治疗后70%达到了部分缓解,56%≥1年的持久缓解。1年后,肿瘤疼痛评分平均降低了2分,疼痛对日常功能、总体健康相关生活质量、力量和关节活动范围等多项功能结局也观察到了有临床意义的改善。其中5人因副作用停药;6人疾病发展。最常见的毒性作用为恶心、呕吐或腹泻、无症状的肌酸磷酸激酶水平升高、痤疮样皮疹及甲沟炎。结论:对于手术无法切除的丛状神经纤维瘤患儿,司美替尼产生了持久的缩小肿瘤作用。儿童哮喘哮喘(asthma)是一种异质性疾病,特点是慢性气道炎症。12岁以下儿童哮喘是最常见的儿童期慢性疾病,约80%的患儿在5岁以前出现症状,咳嗽、哮鸣、呼吸急促、胸闷胸痛是常见的症状。最常见的诱发因素包括病毒性上呼吸道感染(合胞病毒、流感病毒、鼻病毒)、运动、天气、二手烟和变应原(如尘螨、宠物毛发、花粉、霉菌)。《病例队列研究:空气污染和家庭相关因素与儿童哮喘发作和持续性喘息的关系》BMJ,2020年8月(2)研究目的探讨儿童哮喘和持续性喘息发病的危险因素(空气污染和家庭相关因素)。这项全国病例对照研究中随访了1-15岁儿童儿童哮喘发病率升高,与父母患有哮喘(风险比 2.29)、母亲在怀孕期间吸烟(风险比 1.20)相关。儿童哮喘发病率低,与父母受教育程度高(风险比0.72)和父母收入高(风险比 0.85)相关。空气污染物PM2.5和PM10与哮喘的风险增加和持续喘息相关。结论:暴露于空气污染中的儿童更容易患哮喘和持续性喘息,哮喘与父母哮喘病史、父母教育程度和母亲在怀孕期间吸烟有关。《观察性研究:母亲在怀孕期间吸烟影响子女成年后哮喘发作》European Respiratory Journal 2020年7月 (3)研究的目的是确定产前哮喘和成人哮喘发病之间的关系。研究纳入5200名、1966年芬兰北部出生的、31岁前未诊断为哮喘的人群。研究发现孕妇妊娠最后3个月吸烟,其后代31岁至46岁之间哮喘累积发病率(男性为5.1%,女性为8.8%),尤其是与无哮喘病史(风险比9.63)或咳嗽喘息病史(风险比3.21)的后代中有显著相关性。同时在妊娠期吸烟与31岁时子代的用力呼气量(FEV1)/用力肺活量(FVC)比率之间有发现了显著的相关性,在在RUNX1单倍型rs11702779-AA的后代中成年期患哮喘的风险比为5.53。结论:怀孕期间吸烟与后代成年后哮喘累积发病率有关。《观察性研究:空气污染和从出生到成年的哮喘发展》European Respiratory Journal 2020年7月 (4)空气污染对青春期至成年期哮喘发展的影响尚不清楚,研究纳入了3687个参与者,评估空气污染和哮喘发生的年龄的相关关系。研究20岁之前哮喘的发病率,与出生地空气污染物的比例增加相关(接触PM10的风险比为1.09,接触NO2的风险比为1.20)。对近期家庭居住地的空气污染进行分析后,得到了类似的结果。结论:早年暴露在空气污染中,特别是来自机动交通的污染,与儿童、青春期到成年早期罹患哮喘的风险增加有关。《哮喘患儿卧室颗粒物过滤与气道病理生理变化的关系》JAMA Pediatrics,2020年8月 (5)细颗粒物PM2.5是一种普遍存在的空气污染物,可沉积在小气道中,对哮喘起着至关重要的作用。来自杜克大学与北京上海的研究人员合作,研究PM2.5过滤装置的使用是否能改善哮喘患儿的小气道生理学和呼吸系统炎症。研究人员在患儿的卧室里随机安装了真实的过滤设备和假的过滤设备,试验前有2周的洗脱期,研究是在臭氧含量低的季节在中国上海的郊区进行的。研究纳入轻中度哮喘的、共43个、5-13岁的儿童参加了研究。室外PM2.5浓度中度升高(28.6-69.8μg/m3);经过滤的卧室PM2.5浓度比不经过滤降低63.4%。过滤的卧室空气能显著改善气道力学,总气道阻力下降24.4%,减少小气道阻力43.5%,呼气流量峰值也显著改善。这些改善与卧室PM2.5的减少显著相关。总体的小气道功能改善均没有统计学意义,但在不伴有嗜酸性气道炎症的参与者中改善显著(13.2%)。结论:室内PM2.5过滤可以通过改善气道力学和功能,减少炎症,改善哮喘患者肺部的气体流动。《VDKA研究:补充维生素D3对低维生素D和哮喘患儿哮喘加重的影响》JAMA,2020年8月 (6)研究的目的探讨维生素D3的补充是否能改善儿童哮喘和低维生素D水平严重恶化的时间。这项随机、双盲、安慰剂对照临床试验,纳入6-16岁的、哮喘严重发作高危儿童共192人,平均年龄9.8岁,女孩40%维生素D3组的37.5%和安慰剂组的34.4%出现≥1次严重恶化。补充维生素D3并没有显著改善哮喘严重恶化的时间,没有显著改善病毒诱导哮喘严重加重的时间,没有显著改善糖皮质激素剂量减量的患者比例,也没有显著减少糖皮质激素的累积剂量。两组严重不良事件相似。结论:该研究不支持在持续性哮喘和低维生素D水平的儿童维生素D3来预防哮喘加重。《前瞻性队列研究:抗生素的使用减少,影响肠道菌群和儿童哮喘发病率》Lancet Respiratory Medicine,2020年7月 (7)在欧洲和北美的一些地区,儿童哮喘的发病率正在下降;有研究提示婴儿期使用抗生素与哮喘风险增加有关。该研究的目的是验证哮喘发病率的降低是否与抗生素处方减少有关,并验证这种变化是由肠道菌群变化介导的。本研究包括基于人群和前瞻性队列分析,使用加拿大不列颠哥伦比亚省(人口400万·700万)每年抗生素处方率和哮喘诊断率的管理数据进行人群分析。2000 - 2014年,1-4岁儿童的哮喘发病率从27·3‰ 下降到20·2‰,降幅26·0%。发病率的降低与

BrainWaves: A Neurology Podcast
#109 Misnomers in medicine: Low grade glioma

BrainWaves: A Neurology Podcast

Play Episode Listen Later Aug 20, 2020 25:19


A lot can happen in two years. You might have matched into residency, graduated from fellowship, had a kid... Or several phase II trials in low grade glioma research could have been published. Since the original airing of this episode in May 2018, there have been a few updates in neuro-oncology. We'll cover some of the major ones this week in the BrainWaves podcast. Produced by James E. Siegler, Brian Nahed and Jorg Dietrich. Music courtesy of Ian Sutherland, Lovira, and Lee Roosevere. The opening theme was composed by Jimothy Dalton. Sound effects by Mike Koenig and Daniel Simion. Unless otherwise mentioned in the podcast, no competing financial interests exist in the content of this episode. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC, Olivi A, Brem H and Quinones-Hinojosa A. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63:700-7; author reply 707-8. Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR and Mehta MP. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30:3065-70. Schiff D. Low-grade Gliomas. Continuum (Minneap Minn). 2017;23:1564-1579. Wen PY and Huse JT. 2016 World Health Organization Classification of Central Nervous System Tumors. Continuum (Minneap Minn). 2017;23:1531-1547. Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM, Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP and Chakravarti A. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. JAMA Oncol. 2018;4:1405-1409. van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T and Idbaih A. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncol. 2018;19:1170-1179. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ and Fouladi M. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20:1011-1022. Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M and Chakravarti A. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020:JCO1902983. Breen WG, Anderson SK, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R, Galanis E, Buckner JC and Shaw EG. Final report from Intergroup NCCTG 86-72-51 (Alliance): a phase III randomized clinical trial of high-dose versus low-dose radiation for adult low-grade glioma. Neuro Oncol. 2020;22:830-837. Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW and Consortium NFCT. A Phase II Study of Continuous Oral mTOR Inhibitor Everolimus for Recurrent, Radiographic-Progressive Neurofibromatosis Type 1-Associated Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials Consortium Study. Neuro Oncol. 2020.

Healthcare Direkt
v. 25-26: Skillnaden mellan bra och dåliga emissioner

Healthcare Direkt

Play Episode Listen Later Jul 2, 2019 19:22


Healthcare Direkt är programmet där vi pratar om veckans händelser inom life science. I veckans avsnitt, där vi går igenom finansiering av life science bolag, gästas vi av Annika Espander vd för Asperia. Annika Espander har varit med som rådgivare i flera framgångsrika finansieringar. Hon har 25 års erfarenhet som rådgivare och investerare i ledande befattningar inom finansmarknad på bland annat Handelsbanken, Enskilda Securities och Catella samt som styrelseledamot för medicinteknikbolaget Elekta och industrikonglomeratet Lifco. I nyhetsuppdateringen tar vi upp två storförvärv inom sektorn. Dels amerikanska Abbvies förvärv av Allergan för cirka 63 miljarder dollar. Allergan är kanske mest kända för Botox, men har också verksamhet inom ögonsjukdomar, central nervsystemet, mage/tarm samt kvinnohälsa. Vi pratar också om Pfizers köp av Array Biopharma för 11,4 miljarder dollar. Array Biopharma ligger bland annat bakom Astra Zenecas läkemedelskandidat Selumetinib. I linje med veckans tema om finansiering diskuterar vi A1M Pharmas riktade emission om drygt 27 miljoner. Ser du hellre programmet i videoformat? Välkommen att besöka vår kanal på youtube.com/playdirekt

Medicine Matters oncology
SUMIT: Selumetinib in metastatic uveal melanoma (with Paul Nathan)

Medicine Matters oncology

Play Episode Listen Later Jun 24, 2019 10:46


Advisory Board member and study author Paul Nathan, from the Mount Vernon Cancer Centre in Middlesex, UK, discusses the phase III SUMIT trial, which evaluated the addition of the MEK inhibitor selumetinib to dacarbazine in patients with metastatic uveal melanoma. Find more on Medicine Matters oncology This content was originally published on Medicine Matters oncology (https://oncology.medicinematters.com/) on May 4, 2018.

2017 ASCO Annual Meeting
Selumetinib in children with recurrent or refractory low-grade glioma

2017 ASCO Annual Meeting

Play Episode Listen Later Jul 27, 2017 6:06


Dr Fangusaro speaks with ecancer at ASCO 2017 about the results of a phase II multicentre prospective study of the efficacy of the MEK I/II inhibitor selumetinib in children with recurrent and refractory low-grade glioma. There was a 30-40% response rate in patients for whom multiple previous therapies had failed. He notes that selumetinib was fairly well tolerated by patients. The most common toxicities were Grade 1 and 2, and included nausea, diarrhoea, asymptomatic CPK elevation, rashes and paronychia. Other arms of the trial have been expanded based on results in the early groups. Dr Fangusaro is hopeful selumetinib will soon be used as a first-line therapy. The trial is conducted by the Paediatric Brain Tumour Consortium, an NCI funded group overseen by CTEP.

JAMA Editors' Summary: On research in medicine, science, & clinical practice. For physicians, researchers, & clinicians.
Selumetinib for lung cancer, postmarket drug safety, screening for thyroid cancer, and more

JAMA Editors' Summary: On research in medicine, science, & clinical practice. For physicians, researchers, & clinicians.

Play Episode Listen Later May 9, 2017 7:44


May 09, 2017 edition of the weekly JAMA Editors' Summary

FirstWord Pharmaceutical News
FirstWord Pharmaceutical News for Wednesday, July 22, 2015

FirstWord Pharmaceutical News

Play Episode Listen Later Jul 22, 2015 2:21


Melanoma and Skin Cancer
Selumetinib, the first effective drug for advanced melanoma of the eye

Melanoma and Skin Cancer

Play Episode Listen Later Aug 28, 2013 4:14


Dr Richard D. Carvajal talks to ecancer at the 2013 ASCO Annual Meeting about a phase II cross-over study for patients with metastatic melanoma of the eye. The study found that selumetinib resulted in tumour shrinkage in half of all patients treated and a duration of disease control more than twice that achieved with temozolomide.

GRACEcast Lung Cancer Video
Can we target KRAS effectively in advanced NSCLC?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jul 2, 2013 4:04


Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

GRACEcast ALL Subjects audio and video
Can we target KRAS effectively in advanced NSCLC?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Jul 2, 2013 4:04


Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

GRACEcast
Can we target KRAS effectively in advanced NSCLC?

GRACEcast

Play Episode Listen Later Jul 2, 2013 4:04


Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.

GRACEcast
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast Lung Cancer Video
Dr. Heather Wakelee on the Most Promising New Agents and Pathways for Treating Lung Cancer in the Coming Years

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 25, 2013 1:50


Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

GRACEcast ALL Subjects audio and video
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast ALL Subjects audio and video

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast Lung Cancer Video
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast Lung Cancer Video

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast
Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?

GRACEcast

Play Episode Listen Later Mar 1, 2013 1:36


Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

GRACEcast Lung Cancer Video
Is there a new, promising option for people with the most common mutation seen in lung cancer?

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 26, 2013 5:58


Dr. Jack West reviews the encouraging results with selumetinib, a MEK inhibitor, in combination with chemotherapy for patients with advanced NSCLC and a KRAS mutation, the most common molecular marker seen in lung cancer. 

GRACEcast Lung Cancer Video
ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Sep 11, 2012 5:11


Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

GRACEcast Lung Cancer Audio
ASCO 2012 LC Highlights: Dr. Joel Neal on the MEK Inhibitor Selumetinib in KRAS Mutation-Positive NSCLC (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Sep 10, 2012 5:10


Dr. Joel Neal reviews the favorable results with chemo combined with the novel targeted therapy selumetinib, a MEK inhibitor, in KRAS mutatino-positive patients with advanced non-small cell lung cancer (NSCLC).

AACR 2012 Annual Meeting, Chicago
Selumetinib controlled recurrent low-grade serous ovarian cancer: Dr John Farley - Creighton University, Phoenix, Arizona, USA

AACR 2012 Annual Meeting, Chicago

Play Episode Listen Later May 23, 2012 6:30


Selumetinib, a small-molecule MEK inhibitor, demonstrated the ability to control low-grade serous ovarian or peritoneal cancer, according to phase II study results presented at a press conference at the AACR Annual Meeting 2012.

Journal of Clinical Oncology (JCO) Podcast

The term targeted therapy is often used in cancer drug development. This podcast will discuss the study of a mEK inhibitor where the investigators actually looked at the impact on the target as well as whether the drug worked or did not work.

inhibitors mek selumetinib